Last reviewed · How we verify

N-Acetylcysteine Tablets

Guangdong Provincial People's Hospital · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

N-Acetylcysteine Tablets is a Small molecule drug developed by Guangdong Provincial People's Hospital. It is currently FDA-approved.

N-Acetylcysteine tablets are being studied as a potential treatment for conditions such as Parkinson Disease, Rhinosinusitis, and Cannabis Use Disorder. The exact mechanism of action of N-Acetylcysteine is not specified, but it is being investigated in clinical trials, including one titled "FDOPA PET and Nutritional Support in Parkinson's Disease".

At a glance

Generic nameN-Acetylcysteine Tablets
SponsorGuangdong Provincial People's Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about N-Acetylcysteine Tablets

What is N-Acetylcysteine Tablets?

N-Acetylcysteine Tablets is a Small molecule drug developed by Guangdong Provincial People's Hospital.

Who makes N-Acetylcysteine Tablets?

N-Acetylcysteine Tablets is developed and marketed by Guangdong Provincial People's Hospital (see full Guangdong Provincial People's Hospital pipeline at /company/guangdong-provincial-people-s-hospital).

What development phase is N-Acetylcysteine Tablets in?

N-Acetylcysteine Tablets is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing